Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627386 | 1.00 | GAA (0.50) | GAAMAPTHRH3KCNH2KMT2A | |
| SCHEMBL19627364 | 0.98 | GAA (0.48) | GAAMAPTHRH3KCNH2KMT2A | |
| SCHEMBL19627365 | 0.83 | CYP2C19 (0.43) | GAAMAPTHRH3KCNH2KMT2A | |
| SCHEMBL19630955 | 0.81 | GAA (0.53) | GAAMAPTKMT2ATSHRFKBP1A | |
| SCHEMBL19272299 | 0.81 | GAA (0.53) | GAAMAPTKMT2ATSHRFKBP1A | |
| SCHEMBL19627409 | 0.79 | MAPT (0.46) | GAAMAPTKMT2AFKBP1AMEN1 | |
| SCHEMBL19627415 | 0.79 | MAPT (0.46) | GAAMAPTKMT2AFKBP1AMEN1 | |
| SCHEMBL19630961 | 0.79 | GAA (0.50) | GAAMAPTKMT2ATSHRFKBP1A | |
| SCHEMBL19627404 | 0.77 | MAPT (0.43) | GAAMAPTKMT2ATSHRFKBP1A | |
| SCHEMBL13249203 | 0.76 | GAA (0.47) | GAAMAPTKMT2ATSHRFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, NR1H4 | GAA 846/4885MAPT 3863/4885HRH3 879/4885 |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, SLC10A2 | GAA 892/4885MAPT 3933/4885HRH3 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.